Evidence map›Paper›PMID 42750829›Full record

ReviewBME frontiers2026

De Novo Design Strategies of Nanomedicines for Diabetic Wound Microenvironment Remodeling.

Junyi Zhang, Shuo Li, Nina Liu, Zhenyu Wu, Gang Liu, Chao Liu

Abstract readReview
In one paragraph

Review in BME frontiers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junyi ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Shuo LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Nina LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Zhenyu WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Gang LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.
Chao LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID https://orcid.org/0000-0003-1951-2375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic wounds are arrested by a hostile microenvironment of hyperglycemia, inflammation, infection, and hypoxia. Nanomaterials offer solutions, yet existing reviews lack a systematic framework linking their actions to the interconnected pathological network. Here, we present a pathology network-guided analysis. We delineate how engineered nanosystems from metal-based antimicrobials to glucose-responsive nanoreactors and extracellular vesicles can intercept multiple drivers, including advanced glycation end-products, oxidative stress, biofilms, and immune dysregulation. Critically, we propose a temporally phased roadmap that prioritizes neutralization of upstream drivers (hyperglycemia and biofilms) before downstream interventions (reactive oxygen species scavenging, immunomodulation, and angiogenesis), avoiding premature single-target therapy. Beyond efficacy, we critically address design trade-offs: we examine the evidence for metal nanomaterial selectivity toward bacteria versus stressed host cells, confront bacterial adaptive resistance (efflux pumps and biofilm reinforcement), and scrutinize the trade-off, manufacturing scalability, long-term biosafety, and regulatory ambiguities. By integrating mechanistic insights with clinical scalability and regulatory feasibility, we provide a conceptual framework to guide the rational design of next-generation nanomedicines that prioritize genuine synergy over redundant integration, and outline a roadmap for translation.

Identifiers

PMID42750829
PMCPMC13578779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.